Olmesartan-induced enteropathy treated with budesonide

S Kempenaers; J Bogaert; M De Maeyer; P Van Hauthem; M Ramael; P Schoeters

Olmesartan-induced enteropathy treated with budesonide

Acta Gastroenterol Belg. 2019 Apr-Jun;82(2):319-321.

Authors

S Kempenaers¹, J Bogaert², M De Maeyer², P Van Hauthem², M Ramael^{3

4}, P Schoeters²

Affiliations

¹ Faculty of Medicine, University of Leuven, 3000 Leuven, Belgium.
² Department of Gastroenterology, AZ Herentals, 2200 Herentals, Belgium.
³ Department of Pathology, AZ Herentals, 2200 Herentals, Belgium.
⁴ Department of Cytology and Histology, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.

PMID: 31314195

Abstract

Olmesartan, an angiotensin receptor blocker, is a widely spread antihypertensive drug. Seronegative villous atrophy of the small intestine due to olmesartan use was first described in 2012. We present a new case of olmesartan-induced enteropathy and compare it to recent literature. This case might suggest a use of budesonide for treatment.

Keywords: enteropathy; olmesartan-associated; olmesartan-induced; seronegative villous atrophy; sprue-like.

Publication types

Case Reports

MeSH terms

Angiotensin II Type 1 Receptor Blockers / adverse effects*
Antihypertensive Agents / adverse effects*
Budesonide / therapeutic use*
Diarrhea / chemically induced
Diarrhea / drug therapy
Humans
Hypertension / drug therapy
Imidazoles / adverse effects*
Intestinal Diseases / chemically induced*
Intestinal Diseases / drug therapy*
Tetrazoles / adverse effects*

Substances

Angiotensin II Type 1 Receptor Blockers
Antihypertensive Agents
Imidazoles
Tetrazoles
Budesonide
olmesartan

Supplementary concepts

Diarrhea, Chronic, with Villous Atrophy